MiR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer

Cancer Research

Volumn 71, Issue 19, 2011, Pages 6165-6173

  Nishikawa, Eri ^a   Osada, Hirotaka ^a,b   Okazaki, Yasumasa ^a   Arima, Chinatsu ^a   Tomida, Shuta ^a   Tatematsu, Yoshio ^b   Taguchi, Ayumu ^a   Shimada, Yukako ^a   Yanagisawa, Kiyoshi ^c   Yatabe, Yasushi ^b   Toyokuni, Shinya ^a   Sekido, Yoshitaka ^a,b   Takahashi, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 375; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PHOSPHOPROTEINS;

EID: 80053347466     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1020     Document Type: Article

References (33)

1. Takahashi T, Sidransky D. Biology of lung cancer. In:Mason R, Broaddus V, Murray J, Nadel J, editors. Textbook of respiratory medicine. 4th ed. Philadelphia, PA: Elsevier Science; 2005. p. 1311-27.
2. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:8288-98.
3. Du L, Schageman JJ, Irnov, Girard L, Hammond SM, Minna JD, et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 2010;29:75.
4. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007;28:2-12. (Pubitemid 44942621)
5. Osada H, Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011;102:9-17.
6. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6. (Pubitemid 38697282)
7. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32. (Pubitemid 41541436)
8. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007;26:6099-105. (Pubitemid 47373805)
9. Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, et al. Roles of achaete-scute homologue 1 in DKK1 and E-cadherinrepression and neuroendocrine differentiation in lung cancer. Cancer Res 2008;68:1647-55. (Pubitemid 351416548)
10. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005;65:10680-5. (Pubitemid 41713334)
11. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007;98:1845-52. (Pubitemid 350002188)
12. Linnoila RI. Functional facets of the pulmonary neuroendocrine system. Lab Invest 2006;86:425-44.
13. Keller DM, McWeeney S, Arsenlis A, Drouin J, Wright CV, Wang H, et al. Characterization of pancreatic transcription factor Pdx-1 binding sites using promoter microarray and serial analysis of chromatin occupancy. J Biol Chem 2007;282:32084-92. (Pubitemid 350106424)
14. Kapsimali M, Kloosterman WP, De Bruijn E, Rosa F, Plasterk RH, Wilson SW. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol 2007;8:R173.
15. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 2009;106:5813-8.
16. Baroukh NN, van Obberghen E. Function of microRNA-375 and microRNA-124a in pancreas and brain. FEBS J 2009;276: 6509-21.
17. Avnit-Sagi T, Kantorovich L, Kredo-Russo S, Hornstein E, Walker MD. The promoter of the pri-miR-375 gene directs expression selectively to the endocrine pancreas. PLoS One 2009;4:e5033.
18. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192-200.
19. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010;70:2339-49.
20. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010;394:623-7.
21. Abdelmohsen K, Hutchison ER, Lee EK, Kuwano Y, Kim MM, Masuda K, et al. miR-375 inhibits differentiation of neurites by lowering HuD levels. Mol Cell Biol 2010;30:4197-210.
22. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010;20:784-93.
23. De Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010;70:9175-84.
24. Wang K, Degerny C, Xu M, Yang XJ. YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 2009; 87:77-91.
25. Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 2009;8: 49-57.
26. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010;24: 862-74.
27. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164-73.
28. Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 2008;283:27534-46.
29. Oka T, Sudol M. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells 2009;14: 607-15.
30. Ehsanian R, Brown M, Lu H, Yang XP, Pattatheyil A, Yan B, et al. YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010;29:6160-71.
31. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008;32:803-14.
32. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008;15:1752-9.
33. Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A 2011;108: 2270-5.